

Nicoletta Testoni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/854304/nicoletta-testoni-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163
papers

4,666
citations

37
h-index

66
g-index

163
ext. papers

5,109
ext. citations

3.3
avg, IF

3.96
L-index

#	Paper	IF	Citations
163	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2020 , 105, 47-55	3.8	1
162	Venetoclax Plus Hypomethylating Agents for Relapsed/Refractory Acute Myeloid Leukemia (AML) Is Safe and Manageable in the Outpatient Setting. <i>Blood</i> , 2020 , 136, 14-15	2.2	
161	A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis. <i>Blood</i> , 2019 , 134, 1797-1797	2.2	
160	Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	11
159	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018 , 32, 1609-1620	10.7	50
158	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 99	22.4	24
157	A New Gene Expression Profile Signature CRLF2 Overexpression Based Identifies Novel Adult "Triple Negative" Acute Lymphoblastic Leukemia Subgroups. <i>Blood</i> , 2018 , 132, 5284-5284	2.2	
156	Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. <i>Stem Cell Research and Therapy</i> , 2018 , 9, 271	8.3	32
155	Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells. <i>Haematologica</i> , 2017 , 102, 1204-1214	6.6	6
154	Conjunctival and Limbal Transplantation From the Same Living-Related Bone Marrow Donor to Patients With Severe Ocular Graft-vs-Host Disease. <i>JAMA Ophthalmology</i> , 2017 , 135, 1123-1125	3.9	11
153	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2017 ,	10.7	3
152	Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7038-7038	2.2	1
151	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017 , 8, 29906-29913	3.3	14
150	Copy number variants signature in two patients with relapsed acute promyelocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23207-e23207	2.2	
149	Microarray analysis to identify novel copy number alterations in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11622-11622	2.2	
148	Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11611-11611	2.2	
147	Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2479-2486	4	3

146	Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 375-88	5	3
145	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2058-64	1.9	9
144	FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features. <i>American Journal of Hematology</i> , 2016 , 91, E14-6	7.1	2
143	Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. <i>American Journal of Hematology</i> , 2015 , 90, 515-23	7.1	38
142	4q12 translocations with GSX2 expression identify a CD7(+) acute myeloid leukaemia subset. <i>British Journal of Haematology</i> , 2015 , 171, 141-5	4.5	5
141	Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. <i>Oncotarget</i> , 2015 , 6, 31284-94	3.3	15
140	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. <i>BMC Cancer</i> , 2014 , 14, 396	4.8	5
139	The GNAS1 gene in myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2014 , 38, 804-7	2.7	2
138	Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, e101-4	2	9
137	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013 , 92, 1271-80	3	3
136	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013 , 121, 5138-44	2.2	36
135	Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome. <i>Hematology Reports</i> , 2013 , 5, 26-7	0.9	6
134	BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. <i>PLoS ONE</i> , 2013 , 8, e81425	3.7	11
133	Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis. <i>Blood</i> , 2013 , 122, 2622-2622	2.2	1
132	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013 , 122, 1486-1486	2.2	
131	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. <i>Blood</i> , 2013 , 122, 4000-4000	2.2	
130	Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. <i>Blood</i> , 2013 , 122, 3911-3911	2.2	
129	Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4. <i>Blood</i> , 2013 , 122, 1855-1855	2.2	

128	FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. <i>Leukemia Research</i> , 2012 , 36, 37-41	2.7	4
127	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012 , 120, 761-7	2.2	85
126	A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia. <i>Hematology Reports</i> , 2012 , 4, e27	0.9	0
125	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012 , 120, 2601-2601	2.2	4
124	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. <i>Blood</i> , 2012 , 120, 1749-1749	2.2	
123	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 117, 5591-9	2.2	78
122	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011 , 117, 6793-800	2.2	66
121	Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. <i>Leukemia Research</i> , 2011 , 35, 1527-9	2.7	5
120	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2329-35	1.9	4
119	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 118, 453-453	2.2	1
118	Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience. <i>Blood</i> , 2011 , 118, 4261-4261	2.2	
117	Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. <i>British Journal of Haematology</i> , 2010 , 149, 70-8	4.5	7
116	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2748-54	2.2	48
115	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010 , 95, 1415-9	6.6	39
114	Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 199, 76-80		24
113	Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration. <i>Leukemia Research</i> , 2010 , 34, e246-7	2.7	4
112	B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. <i>Leukemia Research</i> , 2010 , 34, e282-5	2.7	33
111	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010 , 116, 359-359	2.2	12

110	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. <i>Blood</i> , 2010 , 116, 4335-4335	2.2	1
109	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. <i>Blood</i> , 2010 , 116, 4338-4338	2.2	1
108	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010 , 116, 1230-1230	2.2	0
107	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. <i>Blood</i> , 2010 , 116, 668-668	2.2	
106	Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16811-6	11.5	88
105	Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. <i>Clinical Cancer Research</i> , 2009 , 15, 1059-63	12.9	27
104	Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. <i>Leukemia Research</i> , 2009 , 33, e218-20	2.7	7
103	Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. <i>Leukemia and Lymphoma</i> , 2009 , 50, 114-8	1.9	6
102	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S51-S52		
101	Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. <i>American Journal of Hematology</i> , 2009 , 84, 215-20	7.1	56
100	The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. <i>Haematologica</i> , 2009 , 94, 205-12	6.6	54
99	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009 , 113, 3428-34	2.2	53
98	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009 , 114, 5191-200	2.2	58
97	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009 , 113, 4497-504	2.2	158
96	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009 , 114, 4939-43	2.2	54
95	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 4933-8	2.2	176
94	AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. <i>Blood</i> , 2009 , 114, 3024-32	2.2	139
93	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. <i>Blood</i> , 2009 , 114, 2176-2176	2.2	1

92	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2205-2205	2.2	4
91	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009 , 114, 860-860	2.2	1
90	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. <i>Blood</i> , 2009 , 114, 2174-2174	2.2	
89	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. <i>Hematology</i> , 2008 , 13, 1-12	2.2	1
88	Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. <i>Haematologica</i> , 2008 , 93, 1792-6	6.6	74
87	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008 , 26, 106-11	2.2	40
86	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , 2008 , 93, 770-4	6.6	49
85	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008 , 93, 1017-24	6.6	16
84	Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. <i>European Journal of Haematology</i> , 2008 , 80, 31-6	3.8	4
83	Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement: clinical implications. <i>Leukemia Research</i> , 2008 , 32, 1941-3	2.7	2
82	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008 , 112, 181-181	2.2	16
81	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008 , 112, 185-185	2.2	8
80	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. <i>Blood</i> , 2008 , 112, 3190-3190	2.2	3
79	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on 7p12 in IKZF1 Gene in a Large Cohort of BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): on Behalf of the GIMEMA ALL Working Party. <i>Blood</i> , 2008 , 112, 428-428	2.2	
78	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. <i>Blood</i> , 2008 , 112, 1497-1497	2.2	
77	Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2007 , 136, 87-95	4.5	17
76	NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. <i>Haematologica</i> , 2007 , 92, 1268-9	6.6	49
75	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007 , 92, 401-4	6.6	150

74	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007 , 92, 1173-9	6.6	177
73	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007 , 92, 101-5	6.6	49
72	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007 , 110, 26-26	2.2	2
71	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 454-9	2.2	34
70	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2006 , 12, 3037-42	12.9	78
69	Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. <i>Journal of Clinical Oncology</i> , 2006 , 24, e4-5	2.2	26
68	Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. <i>Journal of Clinical Oncology</i> , 2006 , 24, e51-2	2.2	52
67	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 469-72	1.9	19
66	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. <i>Blood</i> , 2006 , 108, 3081-3081	2.2	8
65	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. <i>Blood</i> , 2006 , 108, 836-836	2.2	4
64	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. <i>Blood</i> , 2006 , 108, 2308-2308	2.2	
63	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. <i>Blood</i> , 2006 , 108, 2016-2016	2.2	
62	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006 , 108, 4805-4805	2.2	
61	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. <i>Blood</i> , 2006 , 108, 2017-2017	2.2	
60	Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. <i>Blood</i> , 2005 , 106, 35-9	2.2	288
59	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2005 , 131, 172-9	4.5	39
58	Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. <i>Experimental Hematology</i> , 2005 , 33, 1521-30	3.1	27
57	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4100-9	2.2	308

56	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005 , 106, 1857-1857	2.2	1
55	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. <i>Blood</i> , 2005 , 106, 375-375	2.2	2
54	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5474-5474	2.2	
53	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005 , 106, 1100-1100	2.2	
52	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients. <i>Blood</i> , 2005 , 106, 1098-1098	2.2	
51	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. <i>Blood</i> , 2005 , 106, 4857-4857	2.2	
50	Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 4842-4842	2.2	
49	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004 , 151, 85-6		0
48	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2284-90.2	2.2	60
47	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 104, 4245-51	2.2	85
46	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR α Rearrangement treated with Imatinib.. <i>Blood</i> , 2004 , 104, 1507-1507	2.2	1
45	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. <i>Blood</i> , 2004 , 104, 4655-4655	2.2	
44	Imatinib in the Treatment of CML Patients \geq 5 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2004 , 104, 2935-2935	2.2	
43	Heterogeneous Chromosomal Mechanisms Generating the 5'RUNX1/3'CBFA2T1 Gene in Acute Myeloid Leukemia.. <i>Blood</i> , 2004 , 104, 4272-4272	2.2	
42	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.. <i>Blood</i> , 2004 , 104, 4672-4672	2.2	
41	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. <i>Blood</i> , 2004 , 104, 1816-1816	2.2	
40	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 1489-1489	2.2	1
39	First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2004 , 89, 826-31	6.6	121

38	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003 , 102, 1588-94	2.2	100
37	Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. <i>British Journal of Haematology</i> , 2003 , 120, 251-6	4.5	72
36	The cytogenetic response as a surrogate marker of survival. <i>Seminars in Hematology</i> , 2003 , 40, 56-61	4	17
35	The cytogenetic response as a surrogate marker of survival. <i>Seminars in Hematology</i> , 2003 , 40, 56-61	4	2
34	Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. <i>Experimental Hematology</i> , 2002 , 30, 126-34	3.1	35
33	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002 , 99, 443-9	2.2	121
32	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002 , 99, 1527-35	2.2	147
31	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , 2001 , 98, 3074-81	2.2	275
30	Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2000 , 109, 722-8	4.5	25
29	All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2000 , 64, 139-44	3.8	20
28	Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2273-81	2.2	133
27	Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response. <i>Leukemia and Lymphoma</i> , 2000 , 39, 113-20	1.9	2
26	Characterization of 12p molecular events outside ETV6 in complex karyotypes of acute myeloid malignancies. <i>British Journal of Haematology</i> , 1999 , 107, 340-6	4.5	15
25	Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro. <i>European Journal of Haematology</i> , 1998 , 60, 161-5	3.8	18
24	Granulocytic sarcomas: clinical, diagnostic and therapeutical aspects. <i>Leukemia and Lymphoma</i> , 1997 , 24, 349-53	1.9	12
23	FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. <i>Leukemia and Lymphoma</i> , 1996 , 22, 173-6	1.9	7
22	Fingerprinting of HLA-DQA by polymerase chain reaction and heteroduplex analysis. <i>Molecular and Cellular Probes</i> , 1996 , 10, 123-7	3.3	0
21	The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. <i>Stem Cells</i> , 1995 , 13, 428-34	5.8	24

20	Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 1995 , 16, 231-6	1.9	4
19	Four-chromosomes complex translocations in acute promyelocytic leukemia: description of two cases. <i>European Journal of Haematology</i> , 1994 , 52, 129-33	3.8	14
18	t(8;14)(q11;q32) in acute lymphoid leukemia: description of two cases. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 67, 55-8		11
17	Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 113-8	1.9	13
16	Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 1993 , 11 Suppl 1, 51-6	1.9	7
15	The type of BCR/ABL junction does not predict the survival of patients with Ph1-positive chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1993 , 84, 265-8	4.5	18
14	In Vitro Activity of Alpha-Interferon on Granulocyte-Macrophage Precursors in Chronic Myeloid Leukemia (CML): Correlation with Clinical Responsiveness. <i>Leukemia and Lymphoma</i> , 1992 , 6, 155-160	1.9	3
13	Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia. <i>Leukemia Research</i> , 1991 , 15, 289-96	2.7	4
12	Molecular and cytogenetic studies of a patient with Philadelphia-negative, BCR-positive chronic myeloid leukemia and t(12;12)(q13;p12). <i>Genes Chromosomes and Cancer</i> , 1990 , 1, 284-8	5	2
11	Treatment of Ph+ chronic myeloid leukemia by gamma interferon. <i>Blut</i> , 1989 , 59, 15-20		8
10	Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. <i>Cancer Genetics and Cytogenetics</i> , 1989 , 42, 191-201		17
9	Cytogenetic and molecular analyses in Philadelphia chromosome positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1988 , 69, 424-6	4.5	2
8	Philadelphia-positive acute myelomonocytic leukemia with inversion of chromosome 16 and eosinobasophils. <i>American Journal of Hematology</i> , 1988 , 27, 69-71	7.1	20
7	Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantation--results of a European Cooperative Study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 5-13		21
6	Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantation--results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 51-8		16
5	Cytogenetic analyses in 89 patients with secondary hematologic disorders--results of a cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 65-74		23
4	Inversions of chromosome 12 in human malignancies. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 28, 113-8		17
3	Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. <i>Leukemia Research</i> , 1986 , 10, 29-33	2.7	12

- 2 Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: report of four cases. *Cancer Genetics and Cytogenetics*, **1985**, 15, 309-14 8
- 1 Acute nonlymphocytic leukemias and dysmyelopoietic syndromes in patients treated for Hodgkin's lymphoma. *Cancer Genetics and Cytogenetics*, **1983**, 9, 217-26 11